Subscribe
Close
  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Renew

NCGS, Inc. Plans New Corporate Headquarters In Charleston, South Carolina

04/24/2017
NCGS, Inc., a clinical research organization supporting the pharmaceutical industry, is expanding its operations in Charleston, South Carolina. The company is constructing a new corporate headquarters at 16 Charlotte Street, which will bring $10 million of new capital investment and create 80 new jobs.

Founded in 1984, NCGS is a privately-held, international, full-service CRO which specializes in conducting and managing clinical trials. Focusing on complex areas of clinical development, such as oncology, infectious diseases and critical care, NCGS has worked on the approval or expanded approval of 34 drug, biologic and diagnostic products.

“NCGS’ core mission is to help develop new drugs that improve our lives. This is an exciting time of unprecedented discovery in our industry, and NCGS is proud that our success will translate into growth for our beloved Lowcountry community. Our continued expansion and success, not only impacts new jobs, but furthers our philanthropic impact on the community,” NCGS CEO Nancy C.G. Snowden said.

As an incentive, the Coordinating Council for Economic Development has approved job development credits related to this project.

“The fact that the partnership between NCGS and our great state continues to result in growth and success for both parties is something to be proud of. We have one of the friendliest environments for business in the world, and we can’t wait to see what the future has in store for NCGS,” said Governor Henry McMaster.

“Today’s announcement reinforces an increasing trend, that South Carolina is ‘Just right’ for corporate headquarters. We’re excited to celebrate, not only this tremendous new investment from NCGS, but also the 80 new jobs to Charleston County,” Secretary of Commerce Bobby Hitt added.

Exclusive Research